Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ArQule has regained worldwide rights to the AKT program, including the novel oral agent, ARQ 092, covered under collaboration with Daiichi Sankyo.
Subscribe to our email newsletter
The retrieval of rights is based on Daiichi’s decision to conclude a license and co-commercialization agreement with ArQule.
ArQule chief medical officer Brian Schwartz said, "AKT, also known as the serine/threonine kinase PKB, is believed to mediate a number of signal transduction processes and represents a potential therapeutic target for several cancers and other diseases."
ArQule Kinase Inhibitor Platform was leveraged in the development of ARQ 092 selective AKT inhibitor while structure-based drug design methodology is used for optimization.
The AKT signaling pathway usually dysregulated in cancer, plays vital role in cell growth, survival, migration and angiogenesis.